BrightPath Biotherapeutics Co., Ltd. (TSE:4594) announced a private placement of 10,103 units of 14th stock acquisition rights at an issue price of JPY 58 per warrant for gross proceeds of JPY 585,974 on April 7, 2020. The company will issue the stock acquisition rights through third party allotment. The transaction will include participation from existing investor Merrill Lynch Japan Securities Co., Ltd., Investment Arm. The stock acquisition rights are exercisable into 10,103,000 common shares at an exercise price of JPY 204 and will receive gross proceeds of JPY 2,061,597,000 post exercise. The transaction has been approved by the board of directors and is expected to close on April 23, 2020.